Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.
Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.
P T. 2019 Jul;44(7):424-427
Authors: Cook R, Hendifar AE
Abstract
Carcinoid syndrome causes substantial morbidity and reduces quality of life and survival. In a recent clinical trial, 97% of patients reported bowel movement-related issues, abdominal pain, flushing, and low energy. Combining somatostatin analogs with elotristat ethyl provides a new option for managing refractory CS symptoms. Health care providers should consider strategies that take advantage of approved dosing for patients with CS-related diarrhea.
PMID: 31258314 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
More News: Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Health Management | Pain | Pain Management | Practice Management